Clinical Trials

Prostatic Neoplasms, Castration-Resistant

NCT05848011 2026-05-22

A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

Phase 2 Completed

154 enrolled

Prostatic Neoplasms, Castration-Resistant

NCT06717347 2026-05-22

MK-2140-010

1,046 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06890884 2026-05-22

MK-2140-011

Phase 2 Recruiting

594 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06925737 2026-05-22

MK-2400-001

1,440 enrolled

Prostatic Neoplasms

NCT06911502 2026-05-20

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

400 enrolled

Lymphoma, Follicular

NCT06091254 2026-05-19

OLYMPIA-1

822 enrolled

Lymphoma, Follicular

NCT06952803 2026-05-19

EvoPAR-PR02

700 enrolled

Prostatic Neoplasms

NCT06091865 2026-05-15

OLYMPIA-3

904 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06564038 2026-05-14

Soundtrack-E

Phase 1/2 Recruiting

408 enrolled

Phase 3 Active not recruiting

Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT02257736 2026-05-11

An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

982 enrolled 15 charts

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT03431350 2026-05-11

QUEST

136 enrolled 29 charts

Phase 3 Active not recruiting

Prostatic Neoplasms, Castration-Resistant

NCT04497844 2026-05-11

AMPLITUDE

696 enrolled 15 charts 1 FDA

Metastatic Castration-sensitive Prostate Cancer

NCT07225946 2026-05-11

KLK2-PASenger

800 enrolled

Phase 1 Active not recruiting

Prostatic Neoplasms, Castration-Resistant

NCT02123758 2026-05-08

A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer

57 enrolled

Prostatic Neoplasms

NCT03274492 2026-05-08

POLARIX

Phase 3 Completed

1,000 enrolled 1 FDA

Phase 3 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT03748641 2026-05-08

MAGNITUDE

765 enrolled 16 charts 1 FDA

Phase 1 Active not recruiting

Prostatic Neoplasms, Castration-Resistant

NCT04577833 2026-05-08

A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer

136 enrolled

Phase 1 Active not recruiting

Prostatic Neoplasms

NCT04662580 2026-05-08

ARX517

183 enrolled

Prostatic Neoplasms

NCT05818683 2026-05-08

A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

Phase 1 Recruiting

300 enrolled

Metastatic Castration-resistant Prostate Neoplasms

NCT05283720 2026-05-06

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Phase 2 Recruiting

496 enrolled

Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06191744 2026-05-06

EPCORE™FL-2

1,095 enrolled

Phase 1/2 Active not recruiting

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms

NCT04542824 2026-05-05

EPCORE™ NHL-3

78 enrolled

Phase 1/2 Active not recruiting

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT04623541 2026-05-05

EPCORE™ CLL-1

195 enrolled

Phase 1/2 Active not recruiting

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04663347 2026-05-05

EPCORE™ NHL-2

543 enrolled

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT06136624 2026-05-05

OMAHA-003

1,310 enrolled

Prostate Cancer Metastatic

NCT07365995 2026-05-05

A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

736 enrolled